Cargando…

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification

BACKGROUND: Patients with non-muscle-invasive bladder cancer (NMIBC) need accurate estimations of the risk of recurrence and progression. Physicians can offer individualized therapy after identifying high-risk tumors. In our study, we compared the applicability of European Organization for Research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hui, Ding, Weihong, Jiang, Guangliang, Gou, Yuancheng, Sun, Chuanyu, Chen, Zhongqing, Xu, Ke, Xia, Guowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133586/ https://www.ncbi.nlm.nih.gov/pubmed/30200080 http://dx.doi.org/10.1097/MD.0000000000012006

Ejemplares similares

The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer
por: Chen, Zhongqing, et al.
Publicado: (2012)

The value of EORTC risk tables in evaluating recurrent non–muscle–invasive bladder cancer in everyday practice
por: Walczak, Rafał, et al.
Publicado: (2013)

EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in non–muscle–invasive bladder cancer in Polish patients
por: Borkowska, Edyta M., et al.
Publicado: (2013)

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
por: Xylinas, E, et al.
Publicado: (2013)

AUA returns to its former glory in Chicago
por: Masone, Maria Chiara
Publicado: (2023)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)
por: Power, Nicholas E., et al.
Publicado: (2016)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

AB002. AUA guideline: update on Peyronie’s disease
por: Lue, Tom F.
Publicado: (2018)

Road for inclusion and caring in urology starts at AUA 22
por: Masone, Maria Chiara
Publicado: (2022)

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

AB16. Renal trauma: epidemiology, management and the AUA guidelines
por: Breyer, Benjamin N.
Publicado: (2014)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
por: Maruf, Mahir, et al.
Publicado: (2016)

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

The structural basis for specific decoding of AUA by isoleucine tRNA on the ribosome
por: Voorhees, Rebecca M., et al.
Publicado: (2013)

The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after Intravesical Bacillus Calmette-Guerin Instillation
por: Seo, Kyung Won, et al.
Publicado: (2010)

Periostin: a promising target of therapeutical intervention for prostate cancer
por: Sun, Chuanyu, et al.
Publicado: (2011)

Retroperitoneal Laparoscopic Ureterolithotomy for Proximal Ureteral Calculi in Selected Patients
por: Hu, Qingfeng, et al.
Publicado: (2014)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

Updates in prostate cancer detections and treatments – Messages from 2017 EAU and AUA()
por: Xie, Liping, et al.
Publicado: (2018)

Predictive Factors for Achieving the Recommended AUA Daily Urine Production in Patients With Nephrolithiasis
por: Tay, Kimberly, et al.
Publicado: (2019)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis
por: Jobczyk, Mateusz, et al.
Publicado: (2020)

Chronic Unpredictable Mild Stress Accelerates the Growth of Bladder Cancer in a Xenograft Mouse Model
por: Zhou, Qidong, et al.
Publicado: (2020)

Decoding system for the AUA codon by tRNA(Ile) with the UAU anticodon in Mycoplasma mobile
por: Taniguchi, Takaaki, et al.
Publicado: (2013)

Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy
por: Kang, Jung Hun, et al.
Publicado: (2014)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy
por: Rao, Manoj V., et al.
Publicado: (2013)

Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011
por: Schrader, Andres Jan, et al.
Publicado: (2012)

Actin in nonmuscle cells
por: Bonetta, Laura
Publicado: (2005)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Do Standardised Prognostic Algorithms Reflect Local Practice? Application of EORTC Risk Tables for Non-Muscle Invasive (pTa/pT1) Bladder Cancer Recurrence and Progression in a Local Cohort
por: Pillai, Rajiv, et al.
Publicado: (2011)

Non-muscle invasive bladder cancer risk stratification
por: Isharwal, Sumit, et al.
Publicado: (2015)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
por: Wettstein, Marian S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vtrcfrle6jftcptrmigdqbh110